Document Detail

Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
MedLine Citation:
PMID:  16987266     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Extracorporeal photochemotherapy (ECP) has been accepted as a standard therapy in cutaneous T-cell lymphomas (CTCL), a category of lymphomas mainly resistant to conventional therapies. Approximately one half of patients demonstrate a reduction in skin affliction by at least 50% within 12 months of therapy and are categorized as responders to ECP. Predictive criteria for selecting patients who will respond to ECP are lacking. Such criteria would however, be of great benefit. OBJECTIVES: This study compared T-cell clonality and serum levels of soluble interleukin-2 receptor (sIL-2R), lactate dehydrogenase (LD), neopterin, beta2-microglobulin (beta(2)-M) and granzyme B in CTCL patients in order to evaluate their potential usefulness as predictive markers. PATIENTS/METHODS: Serum and T lymphocytes obtained from 16 patients with CTCL receiving ECP treatment were evaluated in an open retrospective study. RESULTS: We found no evident correlation between detected T-cell clonality and response to ECP. The non-responding group had on average a higher level of serum sIL-2R. This difference was significant after 6 and 12 months of therapy, but not pretreatment. An individual reduction in serum sIL-2R, neopterin and beta(2)-M during a 6-month course of ECP was well correlated to clinical remission. CONCLUSIONS: Seven out of 16 patients were classified as responders. Neither T-cell clonality nor any of the serum markers assessed pretreatment could reliably predict the response to ECP treatment. However, the individual relative changes in sIL-2R, neopterin and beta(2)-M during 6 months of ECP treatment coherently displayed correlation to the clinical response, as assessed after 12 months of ECP treatment.
V Rao; K Ryggen; M Aarhaug; H Y Dai; S Jørstad; T Moen
Related Documents :
19757326 - Efficacy and safety of anti-d for treatment of adults with immune thrombocytopenia.
24896526 - Observations of group introductions in lowland gorillas.
24596946 - Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study.
16787876 - Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response ...
15354916 - The addition of clonidine to bupivacaine in combined femoral-sciatic nerve block for an...
19064156 - Neurovascular problems in the athlete's shoulder.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  20     ISSN:  0926-9959     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-21     Completed Date:  2007-01-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1100-7     Citation Subset:  IM    
Department of Laboratory Medicine, Children's and Women's Health, Trondheim, Norwegian University of Science and Technology, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Granzymes / blood
L-Lactate Dehydrogenase / blood
Lymphoma, T-Cell, Cutaneous / therapy*
Middle Aged
Neopterin / blood
Photopheresis / methods*
Receptors, Interleukin-2 / blood
Time Factors
beta 2-Microglobulin / blood
Reg. No./Substance:
0/Receptors, Interleukin-2; 0/beta 2-Microglobulin; 670-65-5/Neopterin; EC Dehydrogenase; EC 3.4.21.-/Granzymes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The inflammatory response in drug-induced acute urticaria: ultrastructural study of the dermal micro...
Next Document:  Clinical features and risk factors for striae distensae in Korean adolescents.